Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dexamethasone + Selinexor |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Selinexor | Xpovio | KPT-330 | Xpovio (selinexor) inhibits CRM1 (XPO1), preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (PMID: 30976603, PMID: 31793336). Xpovio (selinexor) is FDA approved for use in patients with diffuse large B cell lymphoma after two or more prior therapies, in combination with Adexone (dexamethasone) in patients with relapsed or refractory multiple myeloma after at least four prior therapies, and in combination with Velcade (bortezomib) and Adexone (dexamethasone) in patients with multiple myeloma after at least one prior therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02343042 | Phase Ib/II | Bortezomib Dexamethasone + Selinexor Pomalidomide | Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT04414475 | Phase II | Bortezomib + Dexamethasone + Selinexor Dexamethasone + Pomalidomide + Selinexor Dexamethasone + Selinexor | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | Recruiting | ISR | GRC | 0 |
NCT02336815 | Phase II | Dexamethasone + Selinexor | Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies | Completed | USA | GRC | FRA | DEU | BEL | AUT | 0 |